Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 113

Similar articles for PubMed (Select 23761972)

1.

Management of dyslipidemia and hyperglycemia with a fixed-dose combination of sitagliptin and simvastatin.

Steinberg H, Anderson MS, Musliner T, Hanson ME, Engel SS.

Vasc Health Risk Manag. 2013;9:273-82. doi: 10.2147/VHRM.S44330. Epub 2013 May 29. Review.

2.

Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes.

Scheen AJ.

Expert Opin Drug Metab Toxicol. 2012 Jun;8(6):745-58. doi: 10.1517/17425255.2012.686603. Epub 2012 May 16. Review.

PMID:
22587686
3.

The effects of simvastatin on the pharmacokinectics of sitagliptin.

Cerra M, Luo WL, Li SX, Matthews C, O'Neill EA, Wagner JA, Stoch SA, Anderson MS.

J Popul Ther Clin Pharmacol. 2012;19(3):e356-60. Epub 2012 Oct 11.

4.

Bioequivalence of sitagliptin/metformin fixed-dose combination tablets and concomitant administration of sitagliptin and metformin in healthy adult subjects: a randomized, open-label, crossover study.

Migoya EM, Miller JL, Gutierrez M, Zheng W, Johnson-Levonas AO, Liu Q, Matthews CZ, Wagner JA, Gottesdiener KM.

Clin Drug Investig. 2010;30(12):855-66. doi: 10.2165/11538410-000000000-00000.

PMID:
20923244
5.

Effect of sitagliptin on the pharmacokinetics of simvastatin.

Bergman AJ, Cote J, Maes A, Zhao JJ, Roadcap BA, Sun L, Valesky RJ, Yang A, Keymeulen B, Mathijs Z, De Smet M, Laethem T, Davies MJ, Wagner JA, Herman GA.

J Clin Pharmacol. 2009 Apr;49(4):483-8. doi: 10.1177/0091270008330983. Epub 2009 Feb 9. No abstract available.

PMID:
19204138
6.

New combination treatments in the management of diabetes: focus on sitagliptin-metformin.

Green J, Feinglos M.

Vasc Health Risk Manag. 2008;4(4):743-51. Review.

7.

"If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.

Tenenbaum A, Fisman EZ.

Cardiovasc Diabetol. 2010 Jun 15;9:24. doi: 10.1186/1475-2840-9-24.

8.

Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes.

Hanefeld M, Herman GA, Wu M, Mickel C, Sanchez M, Stein PP; Sitagliptin Study 014 Investigators.

Curr Med Res Opin. 2007 Jun;23(6):1329-39. Epub 2007 Apr 30.

PMID:
17559733
9.

Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction.

Tenenbaum A, Fisman EZ.

Cardiovasc Diabetol. 2012 Oct 11;11:125. doi: 10.1186/1475-2840-11-125. Review.

10.

Targeting multiple dyslipidemias with fixed combinations--focus on extended release niacin and simvastatin.

Pandian A, Arora A, Sperling LS, Khan BV.

Vasc Health Risk Manag. 2008;4(5):1001-9. Review.

11.
12.

Sitagliptin as add-on therapy in insulin deficiency: biomarkers of therapeutic efficacy respond differently in type 1 and type 2 diabetes.

Giampietro O, Giampietro C, Bartola LD, Masoni MC, Matteucci E.

Drug Des Devel Ther. 2013;7:99-104. doi: 10.2147/DDDT.S38346. Epub 2013 Feb 14.

13.

Sitagliptin/metformin fixed-dose combination: in patients with type 2 diabetes mellitus.

Chwieduk CM.

Drugs. 2011 Feb 12;71(3):349-61. doi: 10.2165/11206060-000000000-00000. Review.

PMID:
21319871
14.

Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?

Tenenbaum A, Fisman EZ.

Cardiovasc Diabetol. 2012 Nov 14;11:140. doi: 10.1186/1475-2840-11-140. Review.

15.

Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.

Scheen AJ.

Postgrad Med. 2013 May;125(3):7-20. doi: 10.3810/pgm.2013.05.2659. Review.

PMID:
23748503
16.

Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients.

Ayaori M, Iwakami N, Uto-Kondo H, Sato H, Sasaki M, Komatsu T, Iizuka M, Takiguchi S, Yakushiji E, Nakaya K, Yogo M, Ogura M, Takase B, Murakami T, Ikewaki K.

J Am Heart Assoc. 2013 Jan 28;2(1):e003277. doi: 10.1161/JAHA.112.003277.

17.

Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia.

Filippatos TD, Elisaf MS.

Expert Opin Pharmacother. 2011 Aug;12(12):1945-58. doi: 10.1517/14656566.2011.593509. Epub 2011 Jul 8. Review.

PMID:
21736529
18.

Optimal management of combined dyslipidemia: what have we behind statins monotherapy?

Tenenbaum A, Fisman EZ, Motro M, Adler Y.

Adv Cardiol. 2008;45:127-53. doi: 10.1159/0000115192. Review.

PMID:
18230960
19.

Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone.

Bailey CJ, Green BD, Flatt PR.

Expert Opin Investig Drugs. 2010 Aug;19(8):1017-25. doi: 10.1517/13543784.2010.505235. Review.

PMID:
20629618
20.

Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.

Fazio S.

Clin Ther. 2008 Feb;30(2):294-306. doi: 10.1016/j.clinthera.2008.02.004. Review.

PMID:
18343268
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk